BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20237297)

  • 1. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
    Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
    J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
    Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
    J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
    Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
    Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    Clin Immunol; 2001 Jan; 98(1):70-84. PubMed ID: 11141329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
    Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
    Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Flores-Santibáñez F; Cuadra B; Fernández D; Rosemblatt MV; Núñez S; Cruz P; Gálvez-Cancino F; Cárdenas JC; Lladser A; Rosemblatt M; Bono MR; Sauma D
    Front Immunol; 2018; 9():209. PubMed ID: 29472932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection.
    Hamada H; Bassity E; Flies A; Strutt TM; Garcia-Hernandez Mde L; McKinstry KK; Zou T; Swain SL; Dutton RW
    J Immunol; 2013 Jan; 190(1):296-306. PubMed ID: 23197262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment.
    Liu X; Zawidzka EM; Li H; Lesch CA; Dunbar J; Bousley D; Zou W; Hu X; Carter LL
    Cancer Immunol Res; 2019 Jul; 7(7):1054-1063. PubMed ID: 31064778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
    Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
    Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inducible costimulator augments Tc17 cell responses to self and tumor tissue.
    Nelson MH; Kundimi S; Bowers JS; Rogers CE; Huff LW; Schwartz KM; Thyagarajan K; Little EC; Mehrotra S; Cole DJ; Rubinstein MP; Paulos CM
    J Immunol; 2015 Feb; 194(4):1737-47. PubMed ID: 25576595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
    Huang H; Xiang J
    Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.
    Huang H; Hao S; Li F; Ye Z; Yang J; Xiang J
    Immunology; 2007 Feb; 120(2):148-59. PubMed ID: 17274112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.